Currently predicting for Mon, 1 Apr 2024

Trading levels for CLRB

Fibonacci Support & Resistance Levels

Level Price
Resistance R3 4.03 10.91 %
R2 3.90 7.23 %
R1 3.82 4.96 %
Current price: 3.64
Support S1 3.55 -2.39 %
S2 3.47 -4.67 %
S3 3.33 -8.34 %

Accumulated Volume Support & Resistance Levels

Level Price
Resistance R3 4.24 16.64 %
R2 3.65 0.413 %
R1 3.64 0.138 %
Current price 3.64
Support S1 3.47 -4.54%
S2 3.20 -11.97%
S3 2.83 -22.15%

CLRB Predictions History

1 month ago
PredictionBot.Kathy predicted that CLRB for Jan. 29th is going $3.62 (-13.90%)

1 month ago
PredictionBot.Warren predicted that CLRB for Jan. 29th is going $3.67 (-12.78%)

1 month ago
himallal370.412992 predicted that CLRB for Jan. 29th is going

Rank:

2 months ago
goynesq.236280 predicted that CLRB for Jan. 29th is going

3 years ago
jjsheets330 predicted that CLRB for 2021-03-15 is going $4.50 (130.77%)

3 years ago
Jose M Verhelst predicted that CLRB for 2021-03-15 is going

Rank:

3 years ago
JS predicted that CLRB for 2020-12-22 is going $2.49 (-10.11%)

3 years ago
JS predicted that CLRB for 2020-12-18 is going $2.07 (-8.81%)

3 years ago
JS predicted that CLRB for 2020-12-14 is going $2.22 (7.25%)

3 years ago
JS predicted that CLRB for 2020-10-09 is going $1.38 (6.15%)

Click to get the best stock tips daily for free!

About Cellectar Biosciences

Cellectar Biosciences Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study in patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia and B-cell malignancies; Phase 2B clinical study in r/r multiple myeloma (MM) patients;... CLRB Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT